Discovery Café Sessions
Monday, April 8th, 2019, 11:45 am - 1:00 pm
Applying AI to Save Lives During the Opioid Crisis
The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die in this country every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, academic and industry organizations are harnessing AI to develop new tools that can help alleviate this national crisis. This session will discuss some of the AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, as well as some of the concerns around data privacy.
Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS
Bob Burgin, CEO, Amplifire Healthcare Alliance
Carm Huntress, CEO, RxRevu Inc
Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS
Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BWH; Assistant Professor, HMS
Community Hospitals: Key Component in Healthcare Transformation
Community hospitals are the largest sources of patient care in the U.S. As such, they represent a critical frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the key distinctions from academic medical centers? This session will address these and other critical topics that impact community hospitals and their essential, though often overlooked, role in health care.
Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS
Fabien Beckers, PhD, CEO, Arterys
Joanna Geisinger, CEO, TORq Interface
John Miller, MD, Director, Retinal Imaging, MEE; Assistant Professor, Ophthalmology, HMS
Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS
Tal Wenderow, CEO, Beyond Verbal
Digital Management of Diabetes
Across the full spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with artificial pancreas on the horizon. This session will focus on these areas as well as clinical use cases that highlight the value of AI.
Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS
Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BWH; Lecturer, HMS
Joshua Riff, MD, CEO, Onduo
Mental Health and the Promise of AI
Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS
Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry & Medicine, HMS
Christopher Molaro, CEO, Neuroflow
David Silbersweig, MD, Chairman, Department of Psychiatry, BWH; Stanley Cobb Professor of Psychiatry, HMS
From Startup to Impact (Pharma and Diagnostics)
With all the hype surrounding AI, this session will focus on what really matters. Impact! Who is really moving the needle in life sciences today? This session will introduce you to five leading companies who will share their client stories over lunch.
Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS
Alex Zharavoronkov, PhD, CEO, Insilico Medicine, Inc